The 2019 Voluntary Scheme for Branded Medicines Access and Pricing (VPAS) saw the industry agreeing to make payments to the Department of Health and Social Care (DHSC).
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.